 "Suven Life secures three more patents")
Biopharmaceutical company, Suven Life Sciences Limited, has secured one product patent each from Eurasia, Japan and Mexico corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. The patents are valid through 2029.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents. They are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s, attention deficient hyperactivity disorder, Huntington’s, Parkinson’s and Schizophrenia.
With these patents, Suven has a total of 13 patents from Eurasia, 12 from Japan and 17 from Mexico. These patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like Phase-I or Phase-II.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” Venkat Jasti, CEO of Suven, stated in a release.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents. They are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s, attention deficient hyperactivity disorder, Huntington’s, Parkinson’s and Schizophrenia.
With these patents, Suven has a total of 13 patents from Eurasia, 12 from Japan and 17 from Mexico. These patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like Phase-I or Phase-II.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” Venkat Jasti, CEO of Suven, stated in a release.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%